Recent Finacing
Recent Raise
Aiolos Bio is a clinical-stage biopharmaceutical company developing AIO-001, a long-half-life humanized anti-TSLP monoclonal antibody advancing to Phase 2 for moderate-to-severe asthma and other respiratory/inflammatory indications.
